From Yahoo Finance: 2025-06-02 08:12:00

Sanofi SA has agreed to acquire Blueprint Medicines Corporation, including the rare immunology disease medicine Ayvakit/Ayvakyt. The acquisition also includes elenestinib and BLU-808, with a total equity value of approximately $9.1 billion. Blueprint shareholders will receive a contingent value right for potential milestone payments. The acquisition is expected to be completed in the third quarter of 2025 and is immediately accretive to gross margin.

Ayvakit achieved net revenues of $479 million in 2024 and nearly $150 million in Q1 2025, with significant year-on-year growth. Sanofi’s CEO, Paul Hudson, sees the acquisition as a strategic move that complements their rare and immunology portfolios. Additionally, Sanofi exercised its option to exclusively license Nurix Therapeutics, Inc.’s STAT6 program, focusing on type 2 inflammation diseases like atopic dermatitis and asthma.

Under the collaboration agreement, Nurix will receive a $15 million license extension fee from Sanofi, totaling $127 million. Nurix is eligible for additional milestone payments and royalties associated with the STAT6 program. Stock prices for SNY, BPMC, and NRIX experienced fluctuations during the premarket session. Sanofi’s acquisition of Blueprint Medicines and the STAT6 program further solidify their presence in the rare immunology and inflammation treatment space.

Read more: Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout